Compare PCVX & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCVX | CRSP |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.1B |
| IPO Year | 2020 | 2016 |
| Metric | PCVX | CRSP |
|---|---|---|
| Price | $47.53 | $57.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 19 |
| Target Price | ★ $105.00 | $71.50 |
| AVG Volume (30 Days) | 1.2M | ★ 1.7M |
| Earning Date | 02-24-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $38,337,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,299.68 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $27.66 | $30.04 |
| 52 Week High | $93.77 | $78.48 |
| Indicator | PCVX | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 59.10 | 54.68 |
| Support Level | $44.57 | $53.37 |
| Resistance Level | $47.72 | $60.73 |
| Average True Range (ATR) | 2.00 | 2.39 |
| MACD | 0.10 | 0.22 |
| Stochastic Oscillator | 75.11 | 61.53 |
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.